Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Celine Boutros

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

C. Boutros1, N. Chaput2, E. Lanoy3, A. Larive4, C. Mateus5, E. Routier5, S. Roy5, R. Sun6, A. Lancia7, Y. Tao6, N. Ibrahim8, R.M. Khoury-Abboud8, C. Massard9, R. Bahleda9, D. Schwob3, C. Caramella10, L. Cassard11, J. Soria12, C. Robert13, E. Deutsch14

Author affiliations

  • 1 Dermatology Unit, Outpatient Clinic, Department Of Medicine, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 2 Laboratory Of Immunomonitoring In Oncology, University Paris-saclay, Faculty Of Pharmacy, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 3 Biostatistic And Epidemiology Unit, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 4 Biostatistic And Epidemiology Unit, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 5 Dermatology Unit, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 6 Department Of Radiation Oncology, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 7 Department Of Radiation Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 8 Outpatient Clinic, Department Of Medicine, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 9 Ditep, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 10 Department Of Radiology, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 11 Laboratory Of Immunomonitoring In Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 12 Medimmune, Medimmune, 20878 - Gaithersburg/US
  • 13 Dermatology Unit, University Paris-saclay, Faculty Of Medicine, Inserm Unit U981, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 14 Department Of Radiation Oncology, Radiomics Team, Molecular Radiotherapy Inserm U1030, University Paris-saclay, Faculty Of Medicine, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
More

Resources

Abstract 3469

Background

Ipi 10 mg/kg (every 3 weeks for 4 doses) combined with a 3 + 3 dose-escalation design of RT at week 4 (W4) seemed to have antitumor activity in the 19 pts treated in the phase I study Mel-Ipi-Rx from August 2011 to July 2015 (ESMO 2016, 1117P). This ancillary study assesses the impact of ipi + RT on SIAR and TGR variation (ΔTGR) of irradiated (TGRirr) and non-irradiated (TGRnon-irr) lesions.

Methods

Blood samples were collected at baseline (W0), W4 (before 2nd ipi injection) and W6 (after ipi + RT) to phenotype T cells. TGR, defined as an increase in tumor volume during 1 month, was computed for TGRirr, and TGRnon-irr in 2 periods: (i) Reference-TGR (REF-TGR) on W0, and (ii) Experimental-TGR (EXP-TGR) between W0 and 1st evaluation. The ΔTGR between REF-TGR and EXP-TGR was used to assess the treatment (TRT) effect. A negative value reflected a slowdown of disease progression (DP).

Results

Ipi alone was associated with increased effector T cells (TEM), Treg and ICOS+ CD4+ T cells at W4. At W6, only TEM and ICOS+ CD4+ T cells significantly increased, suggesting that RT + ipi could increase activated memory CD4+ T cells rather than Treg cells. CD8+ T cells did not increase at W4 while central memory T cells (TCM) and terminally differentiated (TEMRA) increased between W4 and W6, suggesting that RT + ipi could boost these CD8+ T populations. Increased CD8 from W0 to W4 was significantly correlated to progession-free survival (PFS) (p = 0.0163). Increased CD8 tended to be positively correlated to overall survival (OS) from W0 to W6 (p = 0.0786). Interestingly, a higher effect of RT + ipi seemed to be associated with a deeper ΔTGRnon-irr than ΔTGRirr, although insignificant. The EXP-TGRnon-irr was significantly associated with DP.

Conclusions

RT + ipi was associated with increased CD4+ and CD8+ ICOS+ T cells. Increased CD8+ was significantly associated with PFS. Thus, immune biomarkers may be useful for early response evaluation. The ΔTGRnon-irr lesions could be more important than ΔTGRirr lesions in responding pts and may be related to an abscopal effect. Updated PFS and OS will be presented.

Clinical trial identification

EUDRACT 2010-020317-93 NCT01557114.

Editorial acknowledgement

Legal entity responsible for the study

Eric Deutsch and Caroline Robert are both corresponding authors and contributed equally to the work.

Funding

Has not received any funding.

Disclosure

C. Boutros: Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Speaker Bureau / Expert testimony: Merck. N. Chaput: Research grant / Funding (self): Cytune Pharma; Research grant / Funding (self): BMS; Research grant / Funding (self): Sanofi; Research grant / Funding (institution): GSK; Honoraria (self), Advisory / Consultancy: AstraZeneca. C. Mateus: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Merck. E. Routier: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Pierre Fabre. C. Massard: Honoraria (self), Advisory / Consultancy: AMGEN; Honoraria (self), Advisory / Consultancy: ASTELLAS; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: BeiGene; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Celgene; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Janssen Cilag; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Merck; Non-remunerated activity/ies: AstraZeneca; Non-remunerated activity/ies: Bayer; Non-remunerated activity/ies: BMS; Non-remunerated activity/ies: Johnson and Johnson; Non-remunerated activity/ies: Lilly; Non-remunerated activity/ies: MedImmune; Non-remunerated activity/ies: Merck. C. Caramella: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: MSK; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Amgen. J. Soria: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Astex; Honoraria (self), Advisory / Consultancy: Clovis; Honoraria (self), Advisory / Consultancy: GSK; Honoraria (self), Advisory / Consultancy: GammaMabs; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Roche/genentech; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Servier; Honoraria (self), Advisory / Consultancy: Takeda; Full / Part-time employment, Full time employee since 2017: MedImmune; Shareholder / Stockholder / Stock options: AstraZeneca; Shareholder / Stockholder / Stock options: Gristso. C. Robert: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Merck Serono; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: MSD. E. Deutsch: Honoraria (self), Speaker Bureau / Expert testimony: BMS; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: Boehringer; Honoraria (self), Advisory / Consultancy: MedImmune; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Honoraria (self), Advisory / Consultancy: Accuray; Honoraria (self), Speaker Bureau / Expert testimony: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings